Walvax Biotechnology
SZSE · 300142
Market Cap$19.1B
Revenue$2.4B
Employees1981
Listed OnSZSE
Ticker300142
CEO / ExecMr. Wei Yao
HeadquartersKunming
MarketMainland China
Websitewww.walvax.com
Overview
Walvax Biotechnology Co., Ltd., engages in the research and development, manufacture, and distribution of vaccines in China and internationally. Its vaccine portfolio includes recombinant human papillomavirus bivalent, 13-valent pneumococcal polysaccharide conjugate, 23-valent pneumococcal polysaccharide, group ACYW135 meningococcal polysaccharide, group A and C meningococcal polysaccharide, group A and group C meningococcal conjugate, and haemophilus influenzae type b conjugate vaccines, as wel
Data Note
This record combines exchange-directory fields with selected profile enrichment. Treat market data, leadership and financial figures as directional unless verified against company filings, exchange announcements or the issuer's own disclosures.